Avanos Medical (AVNS) Cash from Financing Activities (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Cash from Financing Activities data on file, last reported at -$3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 89.0% year-over-year to -$3.2 million; the trailing twelve-month figure through Mar 2026 stood at -$11.1 million (up 85.68% YoY), and the FY2025 full-year result was -$37.0 million, up 24.64% from the prior year.
• Cash from Financing Activities eased to -$3.2 million in Q1 2026, from -$2.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $105.7 million in Q1 2022 to a low of -$114.7 million in Q4 2023.
• A 5-year average of -$7.5 million and a median of -$5.0 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 52950.0% in 2022 and tumbled 4057.14% in 2025, its largest moves.
• Tracing AVNS's Cash from Financing Activities over 5 years: stood at -$21.9 million in 2022, then tumbled by 423.74% to -$114.7 million in 2023, then soared by 76.11% to -$27.4 million in 2024, then jumped by 90.15% to -$2.7 million in 2025, then fell by 18.52% to -$3.2 million in 2026.
• Business Quant data shows AVNS's Cash from Financing Activities at -$3.2 million in Q1 2026, -$2.7 million in Q4 2025, and -$2.0 million in Q3 2025.